Back to Stock Dashboard
Sector:
Healthcare
Add to portfolio
SNGX
Soligenix, Inc.
Soligenix, Inc. (SNGX) is rated C+ (2.6/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B+); its weakest is Profitability (D+).
Quantitative Factor Evaluation • Updated
Overall Rating
2.6
/ 5.0
C+
Value
B+
Factor Score
3.7
/ 5.0
Growth
C+
Factor Score
2.5
/ 5.0
Profitability
D+
Factor Score
1.6
/ 5.0
Momentum
C
Factor Score
2.5
/ 5.0
Revisions
C+
Factor Score
2.6
/ 5.0
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
P/E Ratio
-1.3
EV / EBITDA
0.1
Rev Growth YoY
N/A
Gross Margin
0.0%
Price Return 3M
-15.8%
Price Return 12M
-76.5%
Catalyst Signal
0.00
Market Cap
$7.5M
TTM Revenue
N/A
Price / Sales
N/A
ROE
-127.4%
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-15 | B+ (3.7) | C+ (2.5) | D+ (1.6) | C (2.5) | C+ (2.6) | C+ (2.6) |
| 2026-11-08 | A- (3.9) | C+ (2.5) | D- (0.9) | C+ (2.8) | C+ (2.6) | C+ (2.6) |
| 2026-11-01 | B+ (3.7) | C (2.5) | D- (1.0) | C+ (2.6) | C+ (2.7) | C (2.5) |
| 2026-10-25 | B+ (3.7) | C (2.4) | D- (1.0) | D+ (1.8) | C+ (2.6) | C (2.3) |
| 2026-10-18 | B+ (3.7) | C (2.4) | D- (1.0) | D+ (1.7) | C+ (2.6) | C (2.3) |
Page
1
of
4